Association of metabolic syndrome with sensory gating deficits in patients with chronic schizophrenia.
Metabolic syndrome is more prevalent in schizophrenia than in the general population and is associated with an increased rate of morbidity. It has been associated with cognitive impairments in schizophrenia, which are a core deficit in patients with chronic schizophrenia. Sensory gating deficit is also a core deficit in schizophrenia. The principal objective of this study was to investigate the relationship between sensory gating deficit and metabolic syndrome in patients with schizophrenia, after adjusting for key confounding factors. We hypothesized that patients with metabolic syndrome exhibit a higher rate of sensory gating deficit compared to those without metabolic syndrome. This study investigated sensory gating with the auditory event-related potential method by measuring P50 amplitude changes in a double click conditioning-testing procedure in 51 patients with schizophrenia. Patients with metabolic syndrome (n = 14) had a higher rate of sensory gating deficit (P50 suppression <50%) (p < 0.001) compared to those without metabolic syndrome (n = 37). This result remained significant (B = 2.94, Wald = 8.32, p = 0.004) after taking into account 5 potential confounding factors (age, gender, duration of disorder, Fagerström test, presence of clozapine or olanzapine). In patients without metabolic syndrome, sensory gating deficit was linked to a poorer attentional performance (rho = -0.371, p = 0.05). In patients with metabolic syndrome, sensory gating deficit was linked to poorer memory performance (rho = -0.635, p = 0.02). These findings suggest that metabolic syndrome may be linked to sensory gating deficit in patients with schizophrenia and that the relationship between neurocognitive function and sensory gating deficit could be affected by the metabolic status of the patients. Further studies are needed to address the causal relationship between sensory gating deficit related to schizophrenia, cognitive impairments and metabolic syndrome.
Unité de Neurophysiologie et Psychophysiologie, Pôle de Psychiatrie Universitaire, CHU Sainte-Marguerite, 270 Bd Sainte-Marguerite, 13009 Marseille, France; Services d'explorations fonctionnelles du système nerveux, Clinique du sommeil, CHU de Bordeaux, Place Amélie Raba-Leon, 33076 Bordeaux, France; USR CNRS 3413 SANPSY, CHU Pellegrin, Université de Bordeaux, Talence, France. Electronic address: jarthur.micoulaud@gmail.com.
Jean-Arthur
JA
Micoulaud-Franchi
Pôle de Psychiatrie "Solaris", Centre Hospitalier Universitaire de Sainte-Marguerite, 270 Bd de Sainte-Marguerite, 13009 Marseille, France; Laboratoire de santé publique évaluation des systèmes de soins et santé perçue, Université de la Méditerranée - EA 3279 - Faculté de Médecine, 27 bd Jean Moulin, 13385 Marseille Cedex 05, France.
Mélanie
M
Faugere
Laboratoire de santé publique évaluation des systèmes de soins et santé perçue, Université de la Méditerranée - EA 3279 - Faculté de Médecine, 27 bd Jean Moulin, 13385 Marseille Cedex 05, France.
Laurent
L
Boyer
Unité de Neurophysiologie et Psychophysiologie, Pôle de Psychiatrie Universitaire, CHU Sainte-Marguerite, 270 Bd Sainte-Marguerite, 13009 Marseille, France; Pôle de Psychiatrie "Solaris", Centre Hospitalier Universitaire de Sainte-Marguerite, 270 Bd de Sainte-Marguerite, 13009 Marseille, France; Laboratoire de Neurosciences Cognitives (LNC), UMR CNRS 7291, 31 Aix-Marseille Université, Site St Charles, 3 place Victor Hugo, 13331 Marseille Cedex 3, France.
Michel
M
Cermolacce
Pôle de Psychiatrie "Solaris", Centre Hospitalier Universitaire de Sainte-Marguerite, 270 Bd de Sainte-Marguerite, 13009 Marseille, France; Laboratoire de santé publique évaluation des systèmes de soins et santé perçue, Université de la Méditerranée - EA 3279 - Faculté de Médecine, 27 bd Jean Moulin, 13385 Marseille Cedex 05, France.
Raphaëlle
R
Richieri
Pôle de Psychiatrie "Solaris", Centre Hospitalier Universitaire de Sainte-Marguerite, 270 Bd de Sainte-Marguerite, 13009 Marseille, France; Laboratoire de santé publique évaluation des systèmes de soins et santé perçue, Université de la Méditerranée - EA 3279 - Faculté de Médecine, 27 bd Jean Moulin, 13385 Marseille Cedex 05, France.
Catherine
C
Faget
Services d'explorations fonctionnelles du système nerveux, Clinique du sommeil, CHU de Bordeaux, Place Amélie Raba-Leon, 33076 Bordeaux, France; USR CNRS 3413 SANPSY, CHU Pellegrin, Université de Bordeaux, Talence, France.
Pierre
P
Philip
Unité de Neurophysiologie et Psychophysiologie, Pôle de Psychiatrie Universitaire, CHU Sainte-Marguerite, 270 Bd Sainte-Marguerite, 13009 Marseille, France; Pôle de Psychiatrie "Solaris", Centre Hospitalier Universitaire de Sainte-Marguerite, 270 Bd de Sainte-Marguerite, 13009 Marseille, France; Laboratoire de Neurosciences Cognitives (LNC), UMR CNRS 7291, 31 Aix-Marseille Université, Site St Charles, 3 place Victor Hugo, 13331 Marseille Cedex 3, France.
Jean
J
Vion-Dury
Pôle de Psychiatrie "Solaris", Centre Hospitalier Universitaire de Sainte-Marguerite, 270 Bd de Sainte-Marguerite, 13009 Marseille, France; Laboratoire de santé publique évaluation des systèmes de soins et santé perçue, Université de la Méditerranée - EA 3279 - Faculté de Médecine, 27 bd Jean Moulin, 13385 Marseille Cedex 05, France.
Christophe
C
Lancon
D000328:Adult; D000368:Aged; D002908:Chronic Disease; D003071:Cognition / Q000502:physiology; D005071:Evoked Potentials; D005260:Female; D006801:Humans; D008297:Male; D024821:Metabolic Syndrome / Q000378:metabolism / Q000503:physiopathology*; D008875:Middle Aged; D012559:Schizophrenia / Q000378:metabolism / Q000503:physiopathology*; D055139:Sensory Gating / Q000502:physiology*; D055815:Young Adult
Cognitive functioning; Metabolic syndrome; P50 suppression; Schizophrenia; Sensory gating